Pfizer bows first Ibrance TV spot as Novartis revs up with rival breast cancer med Kisqali
30 May 2017
Pfizer has launched its first TV ad for breast cancer drug Ibrance, joining a larger mainstream push for cancer drugs in TV ads and coming hot on the heels of the FDA approval of Novartis' first-ever in-class competitor.
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
29 May 2017
Pfizer’s biosimilar to blockbuster anemia meds Epogen and Procrit won the support of an FDA expert panel on Thursday, moving another step closer to a potential approval.
Less promo, more info: Annual physician poll finds docs want fewer pharma ads, more education
29 May 2017
Enough with the online ads, pharma. That’s one of the key finding from doctors who participated in Manhattan Research's annual "Taking the Pulse" study of physician technology use and attitudes, now in its 15th year.
Drug approvals bounce back as R&D labs churn out new winners
29 May 2017
The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.
Kazakhstan sets fixed prices for 105 medicinal products and medical devices
26 May 2017
The Memorandum became effective on May 23, 2017 and will be valid until the end of this year. The document was signed by the heads of leading pharmaceutical associations of Kazakhstan, including the Association for Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan, Association of International Pharmaceutical Manufacturers in Kazakhstan, Association of Pharmaceutical Distributors of the Republic of Kazakhstan, Association PharmMedIndustry of Kazakhstan.
Russia is establishing a competitive rehabilitation industry
26 May 2017
The Russian Ministry of Industry and Trade has prepared a draft Strategy for Developing the Manufacturing of Rehabilitation-Oriented Industrial Products until 2025.
Syndax Prices Public Offering of Common Stock
24 May 2017
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $49.7 million. The offering is expected to close on May 31, 2017, subject to customary closing conditions.
Russia's Pharmacy Chain sees online sales accounting for 10 percent of total by mid-2018
24 May 2017
Russian health and beauty products retailer Pharmacy Chain 36.6 expects online sales to account for 10 percent of total revenue by mid-2018 from just 1 percent now, its corporate finance director said.
Syndax Announces Proposed Public Offering of Common Stock
23 May 2017
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.
European Medicines Agency issued its 2016 annual report
23 May 2017
The European Medicines Agency (EMA) published 2016 annual report. It focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024
Microbial burden assessment of solid pharmaceutical products
22 April 2024
Seasonal variation of microbial contamination in pharmaceutical cleanrooms
22 April 2024